Sponsor Pipeline

Supernus Pharmaceuticals, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
8
Active Trials
6
Recruiting
1
Phase 3
4
Disease Areas
Active Trials by Phase
Phase 4
1
Phase 3
1
Phase 2
4
Phase 1/2
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT04781140 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children… Attention-Deficit/Hyperactivity Disorder Recruiting
Phase 3
NCT02736656 Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine… Attention-Deficit/Hyperactivity Disorder Active, Not Recruiting
Phase 2
NCT07141329 SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures Focal Onset Seizures Recruiting
NCT07226661 Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder Major Depressive Disorder (MDD) Recruiting
NCT05518578 Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant… Epilepsy Recruiting
NCT06798896 RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With… Focal Onset Seizures Recruiting
Phase 1/2
NCT03474770 BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures Focal Impaired Awareness Seizures Active, Not Recruiting
Not specified
NCT07219927 Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion… Parkinson Disease Recruiting
Disease Areas
Epilepsy (4) ADHD (2) Parkinson's Disease (1) Depression (1)
Get alerts when Supernus Pharmaceuticals, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free